149 related articles for article (PubMed ID: 8447355)
1. Pharmacokinetics of desogestrel.
McClamrock HD; Adashi EY
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1021-8. PubMed ID: 8447355
[TBL] [Abstract][Full Text] [Related]
2. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
Bergink W; Assendorp R; Kloosterboer L; van Lier W; Voortman G; Qvist I
Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2132-7. PubMed ID: 2147817
[TBL] [Abstract][Full Text] [Related]
3. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen.
Sobbrio GA; Granata A; Granese D; D'Arrigo F; Panacea A; Nicita R; Pullè C; Trimarchi F
Clin Exp Obstet Gynecol; 1991; 18(1):43-5. PubMed ID: 1829029
[TBL] [Abstract][Full Text] [Related]
4. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
[TBL] [Abstract][Full Text] [Related]
5. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
Archer DF; Timmer CJ; Lammers P
Fertil Steril; 1994 Apr; 61(4):645-51. PubMed ID: 8150105
[TBL] [Abstract][Full Text] [Related]
7. Desogestrel, norgestimate, and gestodene: the newer progestins.
Kaplan B
Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
Kuhnz W; Schütt B; Power J; Back DJ
Arzneimittelforschung; 1992 Sep; 42(9):1139-41. PubMed ID: 1445482
[TBL] [Abstract][Full Text] [Related]
9. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
Hammond GL; Bocchinfuso WP; Orava M; Smith CL; van den Ende A; van Enk A
Contraception; 1994 Oct; 50(4):301-18. PubMed ID: 7813219
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacology of newer progestogens.
Kuhl H
Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
[TBL] [Abstract][Full Text] [Related]
11. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
[TBL] [Abstract][Full Text] [Related]
12. New knowledge in the physiology of hormonal contraceptives.
Lobo RA; Stanczyk FZ
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
[TBL] [Abstract][Full Text] [Related]
13. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
Jung-Hoffmann C; Fitzner M; Kuhl H
Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
[TBL] [Abstract][Full Text] [Related]
14. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
15. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
16. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.
Back DJ; Houlgrave R; Tjia JF; Ward S; Orme ML
J Steroid Biochem Mol Biol; 1991 Feb; 38(2):219-25. PubMed ID: 2004043
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism.
Jung-Hoffman C; Kuhl H
Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2183-97. PubMed ID: 2147819
[TBL] [Abstract][Full Text] [Related]
18. Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.
Back DJ; Grimmer SF; Shenoy N; Orme ML
Contraception; 1987 Jun; 35(6):619-26. PubMed ID: 2959449
[TBL] [Abstract][Full Text] [Related]
19. Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum.
Kuhnz W; Sostarek D; Gansau C; Louton T; Mahler M
Am J Obstet Gynecol; 1991 Sep; 165(3):596-602. PubMed ID: 1892184
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding.
Bergink EW; Holma P; Pyörälä T
Scand J Clin Lab Invest; 1981 Nov; 41(7):663-8. PubMed ID: 6461916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
